# US 2021/0171603 A1 · Cd80 variant immunomodulatory proteins and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171603 A1
- Document ID: US20210171603A1
- Status: Published application
- Kind: A1
- Application number: 17/163,205
- Filed: 2021-01-29
- Published: 2021-06-10
- Earliest claimed: 2017-03-16
- Assignees: Alpine Immune Sciences, Inc.
- Applicants: Alpine Immune Sciences, Inc.
- Inventors: Ryan SWANSON; Michael KORNACKER; Mark F. MAURER; Dan ARDOUREL; Daniel William DEMONTE; Joseph L. KUIJPER
- Web page: https://patentgrep.com/patent/US20210171603A1

## CPC

- C07K 14/70532: {B7 molecules, e.g. CD80, CD86}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61P 35/00: Antineoplastic agents
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/585: {wherein the target is cancer}
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.

## Claims

### Claim 1

An engineered T cell, comprising a nucleic acid encoding a fusion protein of the formula CD80-linker-Fc, wherein CD80 is a variant CD80 polypeptide comprising the amino acid substitutions H18Y, A26E, E35D, M47L, V68M, A71G and D90G in the amino acid sequence set forth in SEQ ID NO: 2 or a portion thereof comprising the IgV domain, wherein the IgV domain is amino acids 35-141 of SEQ ID NO:1.

### Claim 2 (depends on 1)

The engineered T cell of claim 1, wherein a homodimer of the fusion protein is secretable from the engineered cell.

### Claim 3 (depends on 1)

The engineered T cell of claim 1, wherein the cell further comprises a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR).

### Claim 4 (depends on 1)

The engineered T cell of claim 1, wherein the variant CD80 polypeptide is set forth in SEQ ID NO: 2276.

### Claim 5 (depends on 1)

The engineered T cell of claim 1, wherein the linker has 1-20 amino acid residues.

### Claim 6 (depends on 1)

The engineered T cell of claim 1, wherein the linker is GSGGGS (SEQ ID NO: 1716).

### Claim 7 (depends on 1)

The engineered T cell of claim 1, wherein the Fc is a variant human IgG1 Fc with reduced effector function.

### Claim 8 (depends on 1)

The engineered T cell of claim 1, wherein the Fc is set forth in SEQ ID NO:1712, SEQ ID NO:1713, SEQ ID NO:1714 or SEQ ID NO:1715.

### Claim 9 (depends on 1)

The engineered T cell of claim 1, wherein the variant CD80 polypeptide is set forth in SEQ ID NO:2276, the linker is set forth in SEQ ID NO: 1716 and the Fc is set forth in SEQ ID NO:1712.

### Claim 10 (depends on 1)

The engineered T cell of claim 1, wherein the variant CD80 polypeptide is set forth in SEQ ID NO:2276, the linker is set forth in SEQ ID NO: 1716, and the Fc is set forth in SEQ ID NO:1713.

### Claim 11 (depends on 1)

The engineered T cell of claim 1, wherein the variant CD80 polypeptide is set forth in SEQ ID NO:2276, the linker is set forth in SEQ ID NO: 1716, and the Fc is set forth in SEQ ID NO:1714.

### Claim 12 (depends on 1)

The engineered T cell of claim 1, wherein the variant CD80 polypeptide is set forth in SEQ ID NO:2276, the linker is set forth in SEQ ID NO: 1716, and the Fc is set forth in SEQ ID NO:1715.

### Claim 13 (depends on 2)

The engineered T cell of claim 2, wherein the cell further comprises a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR).

### Claim 14 (depends on 2)

The engineered T cell of claim 2, wherein the variant CD80 polypeptide is set forth in SEQ ID NO: 2276.

### Claim 15 (depends on 2)

The engineered T cell of claim 2, wherein the linker is GSGGGS (SEQ ID NO: 1716).

### Claim 16 (depends on 2)

The engineered T cell of claim 2, wherein the Fc is a variant human IgG1 Fc with reduced effector function.

### Claim 17 (depends on 2)

The engineered T cell of claim 2, wherein the Fc is set forth in SEQ ID NO:1712, SEQ ID NO:1713, SEQ ID NO:1714 or SEQ ID NO:1715.

### Claim 18 (depends on 2)

The engineered T cell of claim 2, wherein the variant CD80 polypeptide is set forth in SEQ ID NO:2276, the linker is set forth in SEQ ID NO: 1716 and the Fc is set forth in SEQ ID NO:1712.

### Claim 19 (depends on 2)

The engineered T cell of claim 2, wherein the variant CD80 polypeptide is set forth in SEQ ID NO:2276, the linker is set forth in SEQ ID NO: 1716, and the Fc is set forth in SEQ ID NO:1713.

### Claim 20 (depends on 2)

The engineered T cell of claim 2, wherein the variant CD80 polypeptide is set forth in SEQ ID NO:2276, the linker is set forth in SEQ ID NO: 1716, and the Fc is set forth in SEQ ID NO:1714.

### Claim 21

An engineered T cell, comprising: (i) a nucleic acid encoding a fusion protein of the formula CD80-linker-Fc, wherein CD80 is a variant CD80 polypeptide set forth in SEQ ID NO:2276, wherein a homodimer of the fusion protein is secretable from the engineered cell; and (ii) a chimeric antigen receptor (CAR).

### Claim 22 (depends on 21)

The engineered T cell of claim 21, wherein the variant CD80 polypeptide is set forth in SEQ ID NO:2276, the linker is set forth in SEQ ID NO: 1716 and the Fc is set forth in SEQ ID NO:1712.

### Claim 23 (depends on 21)

The engineered T cell of claim 21, wherein the variant CD80 polypeptide is set forth in SEQ ID NO:2276, the linker is set forth in SEQ ID NO: 1716, and the Fc is set forth in SEQ ID NO:1713.

### Claim 24 (depends on 21)

The engineered T cell of claim 21, wherein the variant CD80 polypeptide is set forth in SEQ ID NO:2276, the linker is set forth in SEQ ID NO: 1716, and the Fc is set forth in SEQ ID NO:1714.

### Claim 25 (depends on 21)

The engineered T cell of claim 21, wherein the variant CD80 polypeptide is set forth in SEQ ID NO:2276, the linker is set forth in SEQ ID NO: 1716, and the Fc is set forth in SEQ ID NO:1715.

### Claim 26

An engineered T cell, comprising: (i) a nucleic acid encoding a fusion protein of the formula CD80-linker-Fc, wherein CD80 is a variant CD80 polypeptide set forth in SEQ ID NO:2276, wherein a homodimer of the fusion protein is secretable from the engineered cell; and (ii) an engineered T cell receptor (TCR).

### Claim 27 (depends on 26)

The engineered T cell of claim 26, wherein the variant CD80 polypeptide is set forth in SEQ ID NO:2276, the linker is set forth in SEQ ID NO: 1716 and the Fc is set forth in SEQ ID NO:1712.

### Claim 28 (depends on 26)

The engineered T cell of claim 26, wherein the variant CD80 polypeptide is set forth in SEQ ID NO:2276, the linker is set forth in SEQ ID NO: 1716, and the Fc is set forth in SEQ ID NO:1713.

### Claim 29 (depends on 26)

The engineered T cell of claim 26, wherein the variant CD80 polypeptide is set forth in SEQ ID NO:2276, the linker is set forth in SEQ ID NO: 1716, and the Fc is set forth in SEQ ID NO:1714.

### Claim 30 (depends on 26)

The engineered T cell of claim 26, wherein the variant CD80 polypeptide is set forth in SEQ ID NO:2276, the linker is set forth in SEQ ID NO: 1716, and the Fc is set forth in SEQ ID NO:1715.
